Despite $3.44 billion for hospital and specialty services, $2.12bn for primary care and public health, a budget boost of $1.77bn over four years for Pharmac, plus tax relief for inflation-hit businesses, critics of New Zealand’s 2024 Budget said it fails cancer patients, Māori and “kicks the medicines crisis down the road”.
The total spend on health was $29.6bn, up slightly from $26.5bn in last year’s budget, with health minister Dr Shane Reti promising an overall increase in health funding of $16.68bn over this government’s three budgets. National’s election promise to fund 13 specific cancer treatments – including nivolumab (Opdivo) and pembrolizumab (Keytruda), adjuvant treatments for uveal melanoma – whose $280m cost was to be funded by reinstating the $5 prescription fee, was, however, dropped. “Our hearts go out to those living with cancer and their whānau who had their hopes raised by National’s election promise last August, only to see them crushed today,” said Cancer Society chief executive Dr Rachael Hart.
Responding to post-budget criticism from cancer specialists and patients, finance minister Nicola Willis said her government was committed to expanding access to cancer drugs, while prime minister Christopher Luxon agreed it was still a priority and he hoped to make an announcement before the end of the year.
Pharmac’s $1.77bn boost will bring its total budget to $6.3bn over the next four years, said associate health minister David Seymour. However, Dr Ayesha Verrall, the former minister of health, countered that just over $1bn of this is related to increased costs at Pharmac and the new funding will do little more than maintain Pharmac’s status quo. "Hopeful patients and advocates will welcome this funding – but David Seymour needs to be upfront with them about how far it will go," she said.
Other casualties








